Barley Beta-glucan, Glycemic Control, and Appetite

NCT06146322 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-11-24

No results posted yet for this study

Summary

Novel barley varieties high in the soluble fiber β-glucan have the capacity to improve population health through improving glycemic control. Sweetened and unsweetened wholegrain barley foods were tested in a randomized, controlled, crossover human clinical trial to assess impact on postprandial appetite and food intake.

Conditions

  • Diet, Healthy
  • Blood Sugar; High
  • Diabetes
  • Appetite and General Nutritional Disorders
  • Appetitive Behavior

Interventions

OTHER

WR

Unsweetened preload condition: 240 mL white glutinous rice, 250 kcal, 0 g β-glucan

OTHER

LB

Unsweetened preload condition: 240 mL low β-glucan barley, 250 kcal, \~4 g β-glucan

OTHER

MB

Unsweetened preload condition: 240 mL medium β-glucan barley, 250 kcal, \~5 g β-glucan

OTHER

HB

Unsweetened preload condition: 240 mL high β-glucan barley, 250 kcal, \~6 g β-glucan

OTHER

WR+50g HFCS

Sweetened condition with high fructose corn syrup (HFCS): 240 mL white glutinous rice + 50g HFCS, 391 kcal, 0 g β-glucan

OTHER

LB + 50 g HFCS

Sweetened condition with high fructose corn syrup (HFCS): 240 mL low β-glucan barley + 50 g HFCS, 391 kcal, \~4 g β-glucan

OTHER

MB + 50 g HFCS

Sweetened condition with high fructose corn syrup (HFCS): 240 mL medium β-glucan barley + 50 g HFCS, 391 kcal, \~5 g β-glucan

OTHER

HB + 50 g HFCS

Sweetened condition with high fructose corn syrup (HFCS): 240 mL high β-glucan barley + 50 g HFCS, 391 kcal, \~6 g β-glucan

Sponsors & Collaborators

  • Washington State University

    lead OTHER

Principal Investigators

  • Martine Perrigue, PhD, RDN · Washington State University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2020-10-31
Completion
2020-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06146322 on ClinicalTrials.gov